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ABSTRACTS
Gregory L. Moneta, MD, Section EditorAspirin and Extended-Release Dipyridamole vs. Clopidogrel for Recur-
rent Stroke
Sacco RL, Diener H-C, Yusuf S, and the PRoFESS Study Group. New Engl
J Med 2008;359:1238-51.
Conclusion:Rates of recurrent stroke are similar in patients with stroke
treated with aspirin and extended release dipyridamole vs those treated with
clopidogrel.
Summary: Surviving patients with ischemic stroke are at risk for
recurrent stroke. Multiple trials have proven the efficacy of antiplatelet
agents in prevention of recurrent stroke after non-cardioembolic stroke.
Which particular antiplatelet therapy may work best in the prevention of
recurrent stroke is unknown. This trial studied the relative efficacy and safety
of aspirin plus extended-release dipyridamole (ERDP) for prevention of
recurrent stroke compared with patients treated with clopidogrel. This is a
double-blind, two-by-two factorial trial. Patients were randomly assigned to
receive 75 mg of aspirin plus 200 mg of ERDP twice daily, or to receive 75
mg of clopidogrel daily. The primary outcome was first recurrence of stroke.
The secondary end point was a composite of myocardial infarction, stroke, or
death from cardiovascular cause. The trial was designed as a noninferiority
trial with sequential statistic testing of noninferiority, followed by superiority
testing. A total of 20,332 patients were followed up worldwide, with a mean
follow-up of 2.5 years. In patients receiving aspirin and ERDP, recurrent
stroke occurred in 916 (9%). In patients receiving clopidogrel, recurrent
stroke occurred in 898 (8.8%), with a hazard ratio (HR) of 1.01 (95%
confidence interval [CI], 0.92-1.11). The secondary composite outcome
occurred in 13.1% of patients in each group (HR for aspirin/ERDP, 0.99;
95% CI, 0.92-1.07). Patients treated with aspirin/ERDP had 4.1% (n 
419) major hemorrhagic events compared with 3.6% (n  365) in patients
treated with clopidogrel (HR, 1.15; 95% CI, 1.00-1.32) and had more
intracranial hemorrhage (HR, 1.42; 95% CI, 1.11-1.83). The net risk of a
major hemorrhagic event or recurrent stroke was similar in the two groups,
11.7% in the aspirin/ERDP group vs 11.4% in the clopidogrel group (HR,
1.03; 95% CI, 1.95-1.11).
Comments: The study indicates no significant difference between the
use of aspirin/ERDP vs clopidogrel in preventing recurrent stroke. This was
a huge study with high patient numbers and international representation
from 35 countries or regions. The results of the study, therefore, should be
generalizable worldwide. Although the study failed to identify a superior
treatment to prevent recurrent stroke, we now know the expected risk of
recurrent stroke in patients treated according to the study protocol. The
study has also provided us safety and efficacy data for physicians concerning
individual treatment decisions for their patients with ischemic stroke.
Effects of Age and Symptom Status on Silent Ischemic Lesions after
Carotid Stenting With and Without the Use of Distal Filter Devices
Kastrup A, Groschel K, Magele T, et al. Am J Neuroradiol 2008;29:608-12.
Conclusion: Distal filter devices can reduce the incidence of new
diffusion-weighted imaging (DWI) lesions associated with carotid stenting,
but benefit may not necessarily pertain to older and asymptomatic patients.
Summary: Routine use of distal filter devices during carotid angio-
plasty and stenting (CAS) remains controversial. The authors sought to
determine if certain subgroups of patients might benefit compared with
others with the use of filter devices. They used new lesions shown onDWI as
surrogate markers for stroke. Sixty patients underwent CAS with a distal
filtration device and 175 without a distal protective device. All patients were
studied with DWI imaging immediately before and after CAS. Patients were
stratified according to age and symptom status. New ipsilateral DWI lesions
were frequent after CAS in patients with and without neural protective
devices; however, there appeared to be fewer lesions in patients undergoing
protected (52%) vs unprotected CAS (68%). In symptomatic patients, there
was a 56% prevalence of new DWI lesions with protective devices vs 74% in
those without the use of protective devices. In patients aged 75 years,
incidence of DWI lesions was 46% with protective devices vs 67% without
protective devices (all P  .05). In asymptomatic patients and in patients
aged 75 years, the proportion of patients with new lesions and the total
number of new lesions were not significantly different between those treated
with protected and unprotected CAS. For the entire study population, the
incidence of any stroke or death ’30 days was not significantly different
between patients treated with and without neural protection (8.8% vs 5.1%;
P .4). Neurologic complication rates30 days also were not significantly
different among younger, older, symptomatic, or asymptomatic patients
treated with and without protective devices.
272Comment: This is a retrospective and nonrandomized study. The
nature of the study design does not truly permit conclusions about the utility
of neuroprotective devices in symptomatic vs asymptomatic and younger vs
older patients. Nevertheless, the high prevalence of new DWI lesions in
patients treated with and without neuroprotective devices and the lack of
dramatic effects of neuroprotective devices on neurologic events associated
with CASmakes one wonder about the efficacy of neuroprotective devices or
the mechanism of new DWI lesions after CAS, or both.
Ten-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Holman RR, Paul SK, Bethel A, et al. N Engl J Med 2008;359:1577-89.
Conclusion: With 10 years of follow-up, patients with newly diag-
nosed type 2 diabetes initially treated with intensive glucose reducing
therapy have lower long-term risk of myocardial infarction and death from
any cause.
Summary: The United Kingdom Prospective Diabetes Study (UKPDS)
found patients with newly diagnosed type 2 diabetes who received intensive
glucose therapy had a lower risk ofmicrovascular complications than patients
who received only conventional dietary therapy. This study sought to
determine whether improved glucose control persisted in the UKPDS
patients and whether such therapy affected macrovascular outcomes in the
long term.
The original UKPDS study randomized 5102 patients with newly
diagnosed type 2 diabetes. Of these, 4209 were randomly assigned to receive
dietary restriction (conventional therapy) or intensive therapy using sulfo-
nylurea or insulin, or, in overweight patients, metformin. UKPDS clinics
were held for 5 years after the trial ended, and 3277 patients were asked to
attend. No attempts were made to maintain previously assigned therapies.
Patients unable to attend the clinics were queried with annual question-
naires, and questionnaires were used for all patients in years 6 to 10. Data was
analyzed on an intention-to-treat basis with respect to the original random-
ization categories.
Differences in glycated hemoglobin levels among the groups were lost
after the first year of completion of the trial. However, the relative reduction
in risk persisted at 10 years in the sulfonylurea/insulin group for any
diabetes-related end point (9%, P  .04) and microvascular disease (24%,
P  .001). Risk reductions were also found for myocardial infarction (15%,
P  .01) and death from any cause (13%, P  .007). Patients treated with
metformin also had persistent risk reduction for any diabetes-related end
point (21%, P .01), myocardial infarction (33%, P .005), and death from
any cause (27%, P  .002).
Comment: This study, with more than 66,000 person-years of follow-
up, indicates benefit of intensive blood glucose control in patients with
newly diagnosed type 2 diabetes that are followed for 10 years after cessation
of randomization intervention. This occurred despite the fact that early trial
differences in glycated hemoglobin levels between groups were lost over
time; a so-called legacy effect. At first glance this trial would appear to be in
direct opposition to the ADVANCE and ACCORD trials, which appeared in
the New England Journal of Medicine also in 2008 (N Engl J Med 2008;
358:2560-72, and N Engl J Med 2008;358:2545-59). However, the cur-
rent study, and ADVANCE and ACCORD, studied different groups of
patients. The UKPDS group used only newly diagnosed type 2 diabetic
patients. The ADVANCE and ACCORD trials involved higher-risk patients
aged 8 to 12 years older than those in the UKPDS trial and patients who had
been treated for diabetes for 8 to 10 years. A history of macrovascular disease
was also present in about 33% of the patients in ADVANCE and ACCORD
but in only 7.5% of the patients in the UKPDS. Perhaps the most intriguing
result of this study is the sustained legacy effect of early-on intensive glucose
control in patients with newly diagnosed type 2 diabetes. Early aggressive
treatment appears beneficial, suggesting there may be a move away from the
traditional paradigm of initially trying diet alone as therapy for newly
diagnosed type 2 diabetes.
Residual Vein Thrombosis to Establish Duration of Anticoagulation
After a First Episode of Deep Vein Thrombosis: The Duration of
Anticoagulation Based on Compression UltraSonography (DACUS)
Study
Siragusa S, Malato A, Anastasio R, et al. Blood 2008;112:511-5.
Conclusion: Absence of residual venous thrombus (RVT) after a first
episode of deep venous thrombosis (DVT) identifies a group of patients at
very low risk for recurrent DVT after stopping oral anticoagulation therapy.
